Pullman & Comley and Day Pitney welcome experienced attorneys to their teams; Lawyers for Good Government announces award ...

CD&R this week entered exclusive talks with drugmaker Sanofi to buy half of its consumer arm, Opella. Getting burned on ...

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

Data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent in biologic-naive patients with uncontrolled chronic ...

Legend Biotech has reduced Genscript Biotech's control, lowering its voting power below 50%, amid growing US scrutiny of ...

In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves ...

Johnson & Johnson has secured European approval for the subcutaneous formulation of Darzalex, combined with bortezomib, lenalidomide, and dexamethasone, for newly diagnosed multiple myeloma patients ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support US regulatory resubmission by year-end; if ...

At Sanofi, to solve a global problem, we are developing strategies at the local level based on regional requirements. There are many reasons why an individual may not participate in a clinical trial, ...

Sanofi was pleased to invite investors and analysts to attend its Vaccines Investor Event on Wednesday, December 1, 2021. This event provided an in-depth look at our Vaccines business: how we expect ...